A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Doses of Lebrikizumab in Healthy Japanese and Caucasian Volunteers

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Doses of Lebrikizumab in Healthy Japanese and Caucasian Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma; Hodgkin's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 10 Jun 2016 Change in the study design, "parallel assignment " has been added.
    • 07 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Planned end date changed from 1 Aug 2012 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top